Avidity Biosciences (RNA)
(Real Time Quote from BATS)
$46.12 USD
+1.00 (2.22%)
Updated Jul 22, 2024 02:52 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
RNA 46.12 +1.00(2.22%)
Will RNA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNA
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
Other News for RNA
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
3 Best Stocks to Buy Now, 6/26/2024, According to Top Analysts
Avidity Biosciences: A Strong Buy on Innovative Therapeutics and Solid Fundamentals
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors